Physician profile
Thomas C Rothe
NPI 1902854920
$1,288.02
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $258 · 2021: $508 · 2022: $46.78.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $199.04 | 2021-2022 | |
| Amgen INC. | $182.32 | 2019-2021 | |
| Pfizer INC. | $122.31 | 2019-2021 | |
| Allergan, INC. | $116.85 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.73 | 2019-2021 | |
| Glaxosmithkline, LLC. | $86.49 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $61.39 | 2019-2021 | |
| Amarin Pharma, INC. | $49.22 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.57 | 2019-2021 | |
| Astellas Pharma US INC | $44.43 | 2020-2021 | |
| Novo Nordisk INC | $40.63 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $38.91 | 2019-2021 | |
| Abbott Laboratories | $32.61 | 2019 | |
| Sanofi Pasteur INC. | $26.66 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $24.06 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $20.65 | 2019 | |
| Eisai INC. | $19.68 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.53 | 2021 | |
| Lilly USA, LLC | $13.89 | 2021 | |
| Boston Scientific Corporation | $12.57 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.39 | 2021 | |
| Seqirus USA INC | $11.95 | 2021 | |
| Strongbridge US INC. | $11.93 | 2019 | |
| Fidia Pharma USA INC. | $5.21 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Rothe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.